Prostate cancer is the most common malignant neoplasm in men, with more than 164 000 new cases diagnosed in 2018.1 With the advent and availability of prostate-specific antigen (PSA) testing enabling earlier detection of prostate cancer, most men are diagnosed as having localized disease. Here, KLK3 is linked to prostate carcinoma.